anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Cardiovascular disease (CVD) is the main cause of mortality in Rheumatoid Arthritis (RA).
OBJECTIVE: To investigate the effect of biologic disease modifying anti-rheumatic drugs (bDMARDs) on lipids and CVD risk and evaluate associations with changes in systemic inflammation.
METHODS: Patients with RA initiating a bDMARD were evaluated at baseline, 3 and 6 months later. Longitudinal mixed effects models examined the association of individual biologics with changes in lipid levelsm Reynolds Risk Score (RRS) and Framingham risk score. Mediation by CRP, clinical disease activity index (CDAI) or swollen joint count on lipid changes were modeled using structural equation models. The correlation between CRP changes and LDL changes was estimated. Changes of LDL-C at 6 months among patients with low baseline LDL-C (<90 mg/dl) vs higher baseline LDL-C(90-130, and >130 mg/dl) were compared. The association between LDL-C changes across baseline LDL-C groups and disease activity improvement was evaluated.
RESULTS: 1698 bDMARD initiations were analyzed. Patients initiating tocilizumab had a significant increase in lipid levels but RRS at 3 and 6 months was similar across all biologics. Framingham risk score increased for patients treated with tocilizumab. Mediator analyses were statistically significant for the effects of CRP on lipid levels. Increases in LDL-C from baseline were independent of clinical response. An association of changes from baseline CRP and LDL-C were observed across all of the bDMARDs studied.
CONCLUSION: Moderate increases in lipid levels on bDMARD treatment were not associated with an increased CVD risk by RRS regardless of the bDMARD initiated. Changes in CRP were significantly associated with changes in lipids in a mediator analysis.
A computer-implemented method includes generating a workout plan for a user having a user profile. The workout plan includes an exercise selected from a set of exercises stored in the user profile. The exercise has a prescribed weight and a prescribed number of exercise repetitions. The method includes capturing user performance data for the exercise during execution of the workout plan by the user in an exercise environment. The user performance data includes an actual weight used in performance of the exercise and an actual number of exercise repetitions by the user. The method includes determining a new value for the prescribed weight based on a stored value of the prescribed weight in the user profile, the prescribed number of exercise repetitions, and the user performance data. The stored value of the prescribed weight in the user profile is adjusted to the new value for the prescribed weight.
Complete Decongestive Therapy (CDT) is the "gold standard" in lymphedema care and has been found to be efficacious in numerous studies. These studies have varying treatment protocols of intensive phase I CDT with dosing ranging from 2x/wk for a mean of 7.5 wks to 6x/wk until a plateau in arm volumes were achieved. This variability in research does not lend itself to recommendations of evidence-based protocol use of CDT in an outpatient setting.

Although CDT is backed by efficacy studies, the daily dosing given to patients is based on anecdotal rather than evidence-based practice. Because the traditional protocol was developed from "longstanding experience," research is necessary to determine the best dosing of the intensive phase of CDT. The purpose of this study is to investigate what level of dosing in the intensive CDT phase promotes best volume reduction and increased upper extremity function in the breast cancer-related lymphedema patient population. This particular study will answer: What dosing produces best volumetric reduction and upper extremity function in the intensive phase of complete decongestive therapy for outpatients with breast cancer-related lymphedema 2x/wk for 4wks or 4x/wk for 4 wks?
On day 1, subjects will have a allergy skin patch test applied and a routine skin examination. On day 3, the patch test will be removed and documentation of the test sites using iPhone app. On day 5, the final assessment for allergic contact dermatitis will be conducted by a medical professional.
The use of uncrewed aerial vehicles (drones) has increased over the last decade. However, their application in healthcare has not been fully examined, in part, due to regulations preventing flight beyond the visual line of sight. This prospective randomised controlled laboratory study aimed to determine whether the in vitro quality of packed red blood cell components is maintained when transported by drone, beyond visual line of sight. Ten identical pairs of packed red blood cell units were randomly allocated to transport by drone or by ground vehicle (1:1, allocation concealment) 68 km between two hospitals in Northumbria, UK. Markers of blood component quality were compared at 8, 14, 28 and 35 days following blood unit manufacture. There was no statistical difference in haemolysis, potassium concentration, total haemoglobin, glucose and lactate, haematocrit and mean cell volume, between the two groups, up to the date of unit expiry. The temperature of the packed red blood cell units did not deviate outside the recommended 2-10°C for transportation, regardless of the allocated group. Blood component transport was faster by drone, but did not reach statistical significance. This study demonstrates the feasibility and safety of flying blood components by drone between hospitals in the United Kingdom.
FIELD: dentistry.SUBSTANCE: group of inventions concerns a dental curable composition, a method for its preparation and dental filling material based on it. The method for preparing the composition includes mixing polymerizable monomer (A), spherical filler (B) with an average diameter of primary particles from 230 to 290 nm; spherical filler (C) with an average diameter of primary particles from 150 to 350 nm having an average diameter of primary particles different from the diameter of spherical filler (B), and polymerization initiator (D). Fillers (B) and (C) are spherical particles of composite oxide based on silicon dioxide-oxide of a titanium group element; wherein 90% or more of particles that make up each of filler (B) and filler (C) have a diameter in the range of ±5% of the average diameter of primary particles. Polymerizable monomer (A) includes a set (meth)acrylic compounds. The refractive index of monomer (A) at 25°C is from 1.38 to 1.55; of fillers (B) and (C) - from 1.45 to 1.58 at 25°C. Monomer (A) and fillers (B) and (C) satisfy following conditions: nP<nFBand nP<nFC, where nP is the refractive index of polymer obtained by polymerization of monomer (A) measured at 25°C; nFBis the refractive index of filler (B) at 25°C; nFCis the refractive index of filler (C) at 25°C. At the same time, the difference between nFB and nFC indicators and nP indicator is from 0.001 to 0.015. Dental filling material consists of the dental curable composition of the above-mentioned content.EFFECT: composition can have a well-regulated shade of color without the use of dye, pigment, etc. and provides the convenience of application and aesthetics of dental filling material formed from it, the use of which provides filling, as a result of which the appearance of the formed cured product coincides with the appearance of natural teeth.10 cl, 4 tbl, 9 ex
For PRP treatment, 8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection. Patients will receive a single session of PRP treatment.
The patients of this group will be equipped with an electronic wristwatch and will be monitored every day by the physiotherapist (PT) through an application on their mobiles. The PT will follow these patients with a daily motivational session (15 minutes, modality 1 patient: 1 PT) and with an educational program about the definition, importance and benefits of physical activity.
BACKGROUND: Atrial fibrillation (AF) screening after ischemic stroke or transient ischemic attack (TIA) is given high priority in clinical guidelines. However, patient selection, electrocardiogram (ECG) modality and screening duration remains undecided and current recommendations vary.
METHODS: The aim of this study was to investigate the clinical practice of AF screening after ischemic stroke or TIA at Swedish stroke units. In collaboration with the stakeholders of the Swedish Stroke Register (Riksstroke) a digital survey was drafted, then tested and revised by three stroke consultants. The survey consisted of 17 multiple choice/ free text questions and was sent by e-mail to the medical directors at all stroke units in Sweden.
RESULTS: All 72 stroke units in Sweden responded to the survey. Most stroke units reported that ≥ 75% of ischemic stroke (69/72 stroke units) or TIA patients (67/72 stroke units), without previously known AF, were screened for AF. Inpatient telemetry ECG was the method of first-choice in 81% of the units, but 7% reported lack of access. A variety of standard monitoring durations were used for inpatient telemetry ECG. The second most common choice was Holter ECG (17%), also with considerable variations in monitoring duration. Other AF screening modalities were used as a first-choice method (handheld and patch ECG) but less frequently.
CONCLUSIONS: Clinical practice for AF screening after ischemic stroke or TIA differed between Swedish stroke units, both in choice of AF screening methods as well as in monitoring durations. There is an urgent need for evidence and evidence-based recommendations in this field.
TRIAL REGISTRATION: Not applicable.
PURPOSE:To provide the subject therapeutic agent having such effect as to reduce blood cholesterol efficiently in the body, containing, as active ingredient, interleukin-6. CONSTITUTION:The objective therapeutic agent containing, as active ingredient, interleukin-6 produced by cultured human cells. As necessary, this agent is formulated with additive (s) like human serum albumin, gelatin, mannitol, sorbitol, sorbitol, or lactose into a pharmaceutical preparation. Besides injections, this agent can be made into a pharmaceutical preparation suitable for transmucosal administration such as peroral, pernasal, transpulmonary, or transintestinal administration. Its dose is 0.0001-300mug/kg body weight/day. The interleukin-6, because of its presence in the body, is more compatible with the body than synthetic medicines.
Post-surgical abdominal adhesions, although poorly understood, are highly prevalent. The molecular processes underlying their formation remain elusive. This review aims to assess the relationship between neutrophil extracellular traps (NETs) and the generation of postoperative peritoneal adhesions and to discuss methods for mitigating peritoneal adhesions. A keyword or medical subject heading (MeSH) search for all original articles and reviews was performed in PubMed and Google Scholar. It included studies assessing peritoneal adhesion reformation after abdominal surgery from 2003 to 2023. After assessing for eligibility, the selected articles were evaluated using the Critical Appraisal Skills Programme checklist for qualitative research. The search yielded 127 full-text articles for assessment of eligibility, of which 7 studies met our criteria and were subjected to a detailed quality review using the Critical Appraisal Skills Programme (CASP) checklist. The selected studies offer a comprehensive analysis of adhesion pathogenesis with a special focus on the role of neutrophil extracellular traps (NETs) in the development of peritoneal adhesions. Current interventional strategies are examined, including the use of mechanical barriers, advances in regenerative medicine, and targeted molecular therapies. In particular, this review emphasizes the potential of NET-targeted interventions as promising strategies to mitigate postoperative adhesion development. Evidence suggests that in addition to their role in innate defense against infections and autoimmune diseases, NETs also play a crucial role in the formation of peritoneal adhesions after surgery. Therefore, therapeutic strategies that target NETs are emerging as significant considerations for researchers. Continued research is vital to fully elucidate the relationship between NETs and post-surgical adhesion formation to develop effective treatments.
Background and Objectives: The aim of this study was to evaluate the clinical presentation, treatment outcomes, and complications associated with hepatic hydatid cysts in a pediatric population. Materials and Methods: This retrospective study analyzed 214 pediatric patients with liver hydatid cysts, focusing on clinical presentation, treatment outcomes, and associated complications. Patients were classified based on treatment modality, including non-operative management with albendazole, PAIR, and surgical intervention. This study compared cyst characteristics, recurrence rates, and complications such as cysto-biliary fistulas. Results: Among the patients, 68% (n = 145) had a single cyst and 86% (n = 184) were found to have isolated liver cysts. No significant statistical difference was observed between Group 1 and Group 2 in terms of age, gender, and basic laboratory values and general characteristics of the cysts, such as the lobe where the cyst was located, involvement of multiple organs, number of cysts, the state of cyst rupture, and recurrence; no statistically significant difference was found between the groups (p > 0.05 for each comparison). Cyst rupture incidence was 6%, and the average incidence of recurrence was 2%, with a surgical recurrence incidence of 3%. A total of 37 patients had a laparotomy, while 7 had laparoscopic surgery. In total, capitonnage was performed in 68 patients, omentopexy in 4, and cystostomy in 6. Consequently, among the treated patients (PAIR + surgery), the incidence of cysto-biliary fistula was 11%, anaphylaxis was 2%, surgical recurrence was 3%, and the incidence of reoperation (Clavien-Dindo ≥ 3) was 6%. The average follow-up period was 72 months, during which no mortality was observed. Conclusions: We identified key clinical outcomes related to both non-surgical treatments (cyst rupture and recurrence) and surgical groups (cysto-biliary fistulas, anaphylaxis, the need for reoperation, rupture, and recurrence).
Participants followed a low magnesium diet \<260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
Methods and compositions for introducing a RNAi agent into a target cell are provided. In the subject methods, a target cell is first harvested from a living subject, e.g., a mammal. The RNAi agent is then introduced into the target cell, e.g., where the agent may be present in a vector, to produce a RNAi agent containing target cell. The resultant RNAi agent containing cell is then returned to the subject. Also provided are systems and kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications where administration of a RNAi agent to a subject is desired, including the treatment of disease conditions, such as pathogen induced disease conditions, particularly viral pathogen induced disease conditions, e.g., HIV induced disease conditions.
The invention belongs to the technical field of beverage making, and in particular relates to a suaeda salsa beverage and a preparation method thereof. The suaeda salsa beverage comprises the following components by weight percent: 8-10 percent of suaeda salsa, 10-15 percent of glucose, 70-75 percent of purified water, 2-5 percent of sodium bicarbonate and 1-3 percent of ethylparaben. The preparation method comprises the following steps of selecting and cleaning the suaeda salsa, preparing suaeda salsa juice and preparing the finished product. In the invention, the preparation method is simple, and the raw materials used are easily obtained with low cost, so that the production cost is reduced. The suaeda salsa is rich in microelements, vitamins and multiple amino acids, and has functions of eliminating heat and food retention. Sodium ions in the beverage can supplement the body fluid. The suaeda salsa beverage disclosed in the invention can be absorbed by a human body more easily than water, can supplement physical strength in time, is rich in nutrients, and belongs to a rare health-care beverage with very high practical value.
PURPOSE:To obtain a remedy for anemia containing at least one or more polypeptides among the polypeptides BUF-4 and BUF-5 as active ingredients. CONSTITUTION:At least one or more polypeptides BUF-4 and BUF-5 among the polypeptides are added as active ingredients and prepared according to ordinary method to provide the aimed product. The remedy is mainly prepared in an injection (e.g. intravenous, hypodermic or intramuscular injection) and formulated also in form of oral administration of capsule, tablet, etc. The active ingredients are administered in dose of 0.01-100mg/adult.day once-several times. The remedy is useful in treating and preventing anemia, etc., originated in lowering of erythrocyte and hemoglobin caused by malignant such as leukemia, multiple myeloma or lymphoma.
A process for the production of a fusion protein comprising an active portion of a chloramphenicol acetyltransferase (CAT) protein and apolypeptide. The fusion protein may be purified using CAT substrate affinity chromatography. The eucaryotic polypeptide may be calcitonin or a derivative thereof such as calcitonin-glycine. Other polypeptides described include enzymes such as chymosin, prochymosin and preprochymosin, hormones such as ACTH, insulins, and growth hormones and antigenic polypeptides such as foot and mouth disease virus antigenic polypeptide. The fusion protein may be cleaved at a site susceptible to selective enzymic or chemical cleavage to produce free polypeptide. The fusion protein may be used as an immunogen.
With the continuous deepening of genetic research on neurodevelopmental disorders (NDDs), more patients have been identified the causal or candidate genes. However, it is still urgent needed to increase the sample size to confirm the associations between variants and clinical manifestations. We previously performed molecular inversion probe sequencing of autism spectrum disorder (ASD) candidate genes in 1543 ASD patients. In this study, we used the same method to detect de novo variants (DNVs) in 665 NDD patients with intellectual disability (ID) and/or epilepsy (EP) for genetic analysis and diagnosis. We compared findings from ID/EP and ASD patients to improve our understanding of different subgroups of NDDs. We identified 72 novel variants and 39 DNVs. A totally of 5.71 % (38/665) of the patients were genetically diagnosed by this sequencing strategy. ID/EP patients demonstrated a higher prevalence of likely gene disruptive DNVs in ASD genes than the healthy population. Regarding high-risk genes, SCN1A and CKDL5 were more frequently mutated in ID/EP patients than in ASD patients. Our data provide an overview of the mutation burden in ID/EP patients from the perspective of high risk ASD genes, indicating the differences and association of NDDs subgroups.
Aromatic or heterocyclic oxazapines (or thiazepines) of formula (I) and their salts are prepared by, (a) the halogenation of the cpd. of formula (Nb) to produce the cpd. of formula (III) or its free base, (b) fusing the produced cpds. to produce the cpds. of formula (IIa), (C) reacting the produced halogen cpds. with the cpd. of formula ZH. The new cpds. of formula (I) are useful as antihistaminic agents.
This group will be given 100 mcg / 3 ml carbetocin (intravenously) after the clamping of the umbilical cord. If uterine tonus is lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 1 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
Subjects will complete MRC, SGRQ, CAT, and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
The patients were set up in an identical way as with the real tDCS group, but only received active stimulation for 30 seconds, after which the current was gradually stopped. The participants continued wearing the electrodes until the end of the 20 minutes treatment.
The present invention provides novel derivative of β-lactam antibiotics, such as meropenem. The inventive compounds include compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are particles ( e.g ., nanoparticles) and pharmaceutical compositions thereof that are mucus penetrating. The inventive particles and pharmaceutical compositions may be useful in delivering an inventive compound to the respiratory tract of a subject. The invention further provides methods of using and kits including the inventive compounds, particles thereof, and/or pharmaceutical compositions thereof for treating and/or preventing a pulmonary disease ( e.g. , a respiratory tract infection).
Refractory vasodilatory shock (RVS) following massive calcium channel blocker (CCB) overdose remains a challenging clinical entity. Peripheral venoarterial extracorporeal membrane oxygenation (ECMO) has proven useful in several cases of CCB intoxication, however, its use in the pediatric population poses unique challenges given the generally small size of pediatric peripheral vasculature in comparison to the high flow rates necessary for adequate mechanical circulatory support. As a result of these challenges, our group has adopted a "primary" central ECMO cannulation approach to the treatment of children and adolescents admitted to our center with profound RVS after CCB ingestion. We present four cases within the last year using this approach. All patients were successfully discharged from the hospital with no late morbidity at most recent follow-up. Central ECMO support in cases of massive vasodilatory shock following CCB overdose is safe and effective and should be considered early in the clinical course of these critically ill patients.